The efficacy of ciprofloxacin (Bay o 9867), a promising new quiiolone, was compared with the efficacy of azlocillin plus tobramycin in rabbits with experimentally induced Pseudomonas aeruginosa endocarditis. The MBCs of ciprofloxacin, azlocillin, and tobramycin against the test strain were 0.5, 8, and 4 JLg/ml respectively.
titers of P. aeruginosa were 3.0 ± 1.6 log10 CFU/g of vegetation (mean ± standard deviation) for recipients of ciprofloxacin and 3.2 ± 1.3 log10 CFU/g of vegetation for recipients of azlocillin plus tobramycin. These values compared with control titers of 7.3 ± 1.6 CFU/g. These data indicate that at the doses used, ciprofloxacin was as effective as azlocillin plus tobramycin in the treatment of P. aeruginosa endocarditis in rabbits. Since the latter drug combination has proven efficacy, ciprofloxacin deserves further evaluation in the therapy of systemic infections in animal models and in humans.
Ciprofloxacin (Bay o 9867) is a new quinolone carboxylic acid derivative currently being developed for oral and parenteral use (19) . Like nalidixic acid, to which it is structurally related, it is active against most members of the family Enterobacteriaceae in vitro. However, ciprofloxacin is much more active against these organisms and also has an extended spectrum of activity against Pseudomonas aeruginosa, Neisseria gonorrhoeae, Staphylococcus aureus, Haemophilus influenzae, and a wide variety of other organisms (3, 7, 8, 10, 19) . For example, in vitro studies performed in our laboratory indicate that ciprofloxacin has activity equal to or surpassing that of all agents compared against 187 Pseudomonas sp. strains isolated from systemic infections.
In addition, oral administration of ciprofloxacin results in concentrations in sera and tissue fluids that are potentially useful for treatment of systemic infections (5; R. Ziegler, K.-H. Graefe, W. Wingender, W. Gau, H.-J. Zeiler, V. Lietz, and P. Schacht, Program Abstr. Intersci. Conf. Antimicrob. Agents Chemother. 23rd, Las Vegas, Nev., abstr. no. 851, 1983 ). Because of its broad spectrum, potency, and oral efficacy, ciprofloxacin could be useful for oral treatment of systemic infections that in the past required parenteral therapy (e.g., osteomyelitis). Because of the remarkable susceptibility of Pseudomonas sp. to ciprofloxacin, parenteral use of this quinolone might offer advantages over currently available therapy for such infections, in which resistance, drug allergy, and drug toxicity are frequent problems.
The observations described above on the antimicrobial activity and pharmacology of ciprofloxacin led us to compare the activity of this quinolone with that of azlocillin plus tobramycin, a combination which has previously been shown to be an effective regimen in this model (14) of experimentally induced P. aeruginosa endocarditis in rabbits.
MATERIALS AND METHODS
In vitro studies. All 149 P. aeruginosa strains studied were isolated originally from blood and were submitted to the central reference laboratory at the University of Virginia from 74 hospitals in a wide geographic area encompassing five states during a prospective evaluation of emergence of aminoglycoside resistance (18 Preparation of bacteria. The P. aeruginosa strain used in the rabbit experiments was originally isolated from a fatal case of endocarditis at the University of Virginia Hospital. After two passages, the organisms were kept frozen (-70°C) on glass beads; all samples were removed from the same stock before use. For this strain the MBCs of ciprofloxacin, azlocillin, and tobramycin were 0.5, 8, and 4 ±g/ml, respectively; these values reflect the median MBCs against P. aeruginosa for these three compounds based on the 149 strains of P. aeruginosa evaluated in our laboratory. This strain was killed synergistically by using a combination of azlocillin plus tobramycin (each at one-quarter of its MBC) and a time-kill curve quantitative bactericidal analysis in vitro. The organisms were grown for 18 h in 10 ml of Trypticase soy broth (Difco) at 37°C. After centrifugation at 3,000 rpm for 15 min, the organisms were washed three times in physiological saline. The pellet was suspended in 5 ml of physiological saline and placed on ice until 5 min before inoculation. The inoculum size was determined by serial 10-fold dilutions in physiological saline; samples were spread onto Trypticase soy agar plates for quantitation at the time of inoculation into rabbits.
Production of endocarditis. Endocarditis was induced in 2-to 3-kg New Zealand White rabbits by using modifications of previously described techniques (1, 2, [13] [14] [15] 20) . A polyethylene catheter (type PE-90 Intramedic; Clay-Adams, Parsippany, N.J.) was introduced through the right carotid artery and threaded across the aortic valve after adequate anesthesia was induced with intramuscular ketamine (35 mg/kg) and xylazine (5 mg/kg). The catheter was left in place within the left ventricle for 1 h. Previous studies have shown that this period of valvular trauma uniformly produces nonbacterial thrombotic endocarditis (13, 16) . After 1 h of valvular trauma, 6 x 108 CFU of P. aeruginosa (see above) in 1.0 ml of physiological saline was injected intravenously via an ear vein. This inoculum uniformly produces infective endocarditis, as determined by quantitative valve cultures in control animals, and represents a 100% lethal dose in this experimental model. The catheter was removed approximately 5 mmn after injection of the bacterial inoculum, and the neck wound was closed. Blood cultures and temperatures were obtained 24 h later. Intramuscular treatment was then begun and administered every 8 h with either ciprofloxacin (50 mg/kg) or azlocillin (200 mg/kg) plus tobramycin (5 mg/kg). Treatment was continued for a total of 4 days. On the second day of therapy, blood was drawn 0.5, 1.0, 1.5, 2, 3, 4, 6, and 8 h after dosing to determine antibiotic concentrations. Peak and trough serum samples for determinations of inhibitory and bactericidal titers were also obtained on the second day of therapy.
The animals were sacrificed with an overdose of pentobarbital at intervals after the last dose of antibiotic sufficient to allow the serum inhibitory titer to fall below 1:2 for that antibiotic or combination. These time intervals were 16 h for rabbits treated with ciprofloxacin and 8 h for rabbits treated with azlocillin plus tobramycin, as determined by frequent determinations of serum concentrations after the last dose of drug in rabbits with experimentally induced Pseudomonas endocarditis. In one experiment, eight animals (four in each therapy group) were observed for relapse after 4 days of treatment. The animals were sacrificed when recurrent bacteremia was documented by daily blood cultures or on day 10 after inoculation, whichever occurred first. After sacrifice, the hearts and kidneys were removed aseptically. A representative wedge from the upper pole of the left kidney was obtained and weighed (-1 to 2 g), and the aortic valve and vegetations were removed from the heart and weighed (0.3 to 0.5 g). Previous studies revealed insignificant differences (when data were expressed as CFU per gram) in kidney samples that were randomly chosen from both kidneys of varying sizes from infected rabbits. 32-fold more active than azlocillin (MIC90, 16 ,ug/ml; range, 2 to 32 jig/ml), a potent anti-Pseudomonas penicillin in vitro.
Ciprofloxacin was 8-to 32-fold more active than imipenem, aztreonam, and cefoperazone against the blood isolates of P. aeruginosa. Moxalactam was the least active agent tested (MIC90, 32 ,ug/ml; range, 4 to >128 ,ug/ml) against these strains. Ciprofloxacin was also very active against Pseudomonas strains that were not members of the species P. aeruginosa (data not shown).
Results of therapy. The results of therapy are summarized in Table 1 . There were significant reductions in the numbers of organisms in the aortic vegetations and kidneys of both treatment groups compared with the control group (P < 0.001). However, there was no significant difference between the two treatment groups with respect to the number of organisms in the aortic vegetations or in the kidneys or the number of valves rendered sterile. The three groups were comparable with respect to number of positive blood cultures (>97%) and degree of fever (uniformly .39.6"C) before the initiation of therapy. Only animals with positive blood cultures before the initiation of therapy were included in the analysis. None of the surviving bacteria was resistant to the study drug(s), as determined by surface plating on agar containing relevant concentrations (twice the MBC) of each agent. None of the control animals yielded sterile vegetations at sacrifice after 5 days; in parallel experiments, all five untreated rabbits died of endocarditis between 10 and 18 days after inoculation with a mean of 8.2 log10 CFU of P. aeruginosa per g of vegetation. Relapse was relatively common after the 4-day treatment regimens used in this study. For example, three of four animals treated with azlocillin plus tobramycin for 4 days relapsed (new positive blood culture or death before day 10 after inoculation), compared with one of four animals in the ciprofloxacin group (P > 0.05).
Concentrations of test agents in serum. The concentrations of azlocillin and tobramycin in the sera of treated rabbits (n = 9) are shown in Fig.1 . The levels of ciprofloxacin in the sera of rabbits (n = 10) with experimental Pseudomonas endocarditis are shown in Fig. 2 . The peak serum level was reached 1 h after intramuscular injection. The mean peak concentration was 1.81 ,ug/ml. Of particular note is the long half-life of ciprofloxacin (terminal ,B half-life, 9.7 h), which resulted in a serum level of 0.96 ,ug/ml 8 h after administration. Nearly identical concentrations were obtained in peak and trough samples on day 3 of therapy; no significant accumulation was noted with this regimen (dose every 8 h) in this rabbit model. Serum bactericidal activity. The median peak bactericidal titers were identical in the ciprofloxacin-treated group (1:8; range, 1:4 to 1:32) and the group treated with azlocillin plus tobramycin (1:8; range, 1:2 to 1:256). However, the trough levels were quite different. All animals except one in the group treated with azlocillin plus tobramycin had trough bactericidal titers of <1:2, whereas the median trough bactericidal titer for rabbits given ciprofloxacin was 1:4 (range, 1:2 to 1:16). These trough bactericidal titers correlate well with the serum antibiotic concentrations observed 8 h after administration; azlocillin and tobramycin were almost undetectable, whereas concentrations still above the MBC of the test organism were found in the ciprofloxacin-treated group. DISCUSSION P. aeruginosa endocarditis, although uncommon in the general population, is now a formidable problem in parenteral drug abusers (4, 11) . Despite recent progress in antibiotic therapy of this type of infection, long courses of frequently toxic antibiotics (often with the development of resistance) make this form of endocarditis particularly difficult to treat. Despite combined medical and surgical management, mortality for right-sided disease is -20%, and mortality for left-sided disease is-67% (11) . In many cases of right-sided disease (-50%), tricuspid (and occasionally pulmonic) valvulectomy is necessary due to persistent bacteremia afer 2 weeks of therapy or relapse after 6 weeks of therapy (11) . Immediate valve replacement is now recommended for all cases of left-sided P. aeruginosa endocarditis (11) .
The in vitro studies done in our laboratory and elsewhere indicate that ciprofloxacin is very active against Pseudomonas sp. and members of the Enterobacteriaceae, including aminoglycoside-resistant strains and mapy ,-lactamaseproducing strains (3, 7, 8, 10, 19) . Ciprofloxacin was the most active agent tested (MIC90, 0.5 ,ug/ml) against 149 blood isolates of P. aeruginosa obtained from patients distributed over a wide geographic area. Ciprofloxacin was 8-to >32-fold more active than ceftazidime, cefoperazone, moxalactam, imipenem, aztreonam, and tobramycin against these strains.
Our results clearly demonstrate that serum bactericidal activity adequate for treatment of systemic infections can be attained in rabbits with parenteral administration of ciprofloxacin and that the efficacy of this agent against P. aeruginosa endocarditis in rabbits is comparable to that of azlocillin plus tobramycin, a combination previously shown to be effective (14, 15) at dosages which produce serum concentrations analagous to those attained in humans after standard parenteral regimens (6, 9, 12, 14) .
It is interesting that the azlocillin-tobramycin regimen (whose serum bactericidal titers were <1:2 at the end of each observation will require larger numbers of animals. Studies on the efficacy of longer treatment courses of established endocarditis are clearly warranted.
The concentrations of ciprofloxacin in serum obtained in rabbits after intramuscular administration of 50 mg/kg (peak, 1.81 p.g/ml) are comparable to those reported in humans after a 500-mg oral dose (peak, 1.6 to 2.4 ,ug/ml) (5). The level of tissue penetration of ciprofloxacin, as determined by the blister fluid method, has been estimated at -57% (5). Data on ciprofloxacin kinetics in humans after parenteral dosing will be forthcoming. However, the P half-life after oral dosing has been reported to be 3.7 to 9.9 and 3.9 h in two studies (5; Ziegler et al., 23rd ICAAC, abstr. no. 851). This long half-life suggests that widely spaced dosing intervals (e.g., every 12 h or longer) may be possible in humans. These data from humans correlate well with the half-life of 9.7 h that we observed in rabbits and with the persistence of effective bactericidal titers for up to 8 h after an intramuscular dose of 50 mg/kg.
Ciprofloxacin and related new quinolones have been proposed for potential use in (i) urinary tract infections, (ii) treatment and prophylaxis of enteric infections, (iii) gut decontamination in neutropenic patients, and (iv) prevention of infections after abdominal surgery and extensive burns. Based on the results of our study, the preliminary reports of human pharmacokinetics, and the excellent in vitro activity of ciprofloxacin against many pathogens, there may be other uses, such as (i) therapy of systemic infections (e.g., endocarditis or septicemia) due to susceptible organisms and (ii) oral therapy for infections that are usually difficult to treat or require prolonged therapy or both (e.g., osteomyelitis).
This report is the first record of successful therapy of a serious experimental systemic infection with ciprofloxacin. Similar excellent results were reported recently for enoxacin (CI-919) therapy of experimental Enterobacter aerogenes endocarditis in rabbits compared with cefoperazone (J. A. Boscia, J. A. Kobasa, and D. Kaye, Program Abstr. Intersci. Conf. Antimicrob. Agents Chemother. 23rd, Las Vegas, Nev., abstr. no. 381, 1983). Ciprofloxacin and related quinolones deserve further evaluation in therapy of systemic bacterial infections in animals and humans.
